This site uses third parties to own and optimize your navigation and perform analytical work cookies. If you continue browsing, consider that you accept its use.
You can learn more at our Cookie Policy.


  • Innoprot
    • Productos
      • Stable Cell Lines
        • Stable Cell Lines for Drug Screening in CNS

APP Processing Assay Cell Line - Secretases Activity Assay

Reference: P30701

Get your Price

Data Sheet

Alzheimer’s Disease (AD) is characterized by brain depositions of the beta amyloid (bA). The bA is the amyloid precursor protein (APP) digestion product, which is released from the cell after b-secretase and  g-secretase proteolysis. A novel fluorescence-based assay cell line for secretases activity screening of new inhibitors has been developed.

Innoprot has developed an APP-tGFP MDCK stable cell line which allows to perform assays to oversee the endogenous secretase proteolytic process in living cells, allowing the identification of β-secretase and γ-secretase inhibitors in your screening campaings. We offer this cell line as a “stable cell line” but we also offer vials of division-arrested cells (DA cells) in order to perform a small number of assays. Each vial of these DA cells contains 2 million cells, an enough number of cells to perform a complete experiment in a 96 well-plate.

Assay Details

γ and β secretase commercial inhibitors and a siRNA for BACE1 have been used to perform a High content analysis using this model. Results indicated that the pharmacological inhibition of secretases implicated in AD remains a valid strategy for drug screening.

Therefore, this cellular model has been used to monitor the secretases activity in vivo treated with a library compounds in an automatic epifluorescent imaging system to acquire and analyze how robust the model is. After treatments, images obtained were analyzed using Attovision software from Becton Dickinson and fluorescent vesicles into the citoplasm were quantified.

Results indicate that the detecting dynamyc range is dependent on the inhibitor biophysics and biochemical characteristics and the treatment time. This retention assay was validated with an average of Z´= 0.71+/- 0.01 for High Content Screening with a 72 hours treatment.

  • (More information and results: see data sheet or request us the poster of the product)


  • This model permits evaluate a lybrary of compounds, candidates to inhibitors, in living cells studying the vesicles retention
  • This model provide a strategy to evaluate drug against secretases activity without the necessity to be permeable. 
  • This model allows to analyse in the space and time the compund effect in a multiparametric manner.


Related Products/Services

© Innoprot 2008 - Cell Based Assays for Drug Discovery Screening - Cookie Policy